MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Symptomatic brain calcifications in two patients with JAM2 monoallelic variants.

S. Andretta, G. Bonato, M. Mainardi, L. Salviati, A. Antonini, M. Carecchio (Padova, Italy)

Meeting: 2022 International Congress

Abstract Number: 840

Keywords: Calcium

Category: Rare Genetic and Metabolic Diseases

Objective: To describe two subjects carrying monoallelic JAM2 genetic variant associated with brain calcification.

Background: Primary Familial Brain Calcification (PFBC) is a rare neurodegenerative disorder characterized by cerebral calcium deposition in basal ganglia and other cerebral and cerebellar regions. Clinical presentation features hypo/hyperkinetic movement disorders, cognitive impairment, psychiatric manifestations, headache and seizures.
Mutations in 6 genes have been identified so far: SLC20A2, PDGFRB, PDGFB, XPR1 (autosomal dominant inheritance) and MYORG and JAM2 (autosomal recessive inheritance). More than 50% of patients do not carry mutations in these genes, suggesting the existence of additional, still undiscovered genes.

Method: We describe two patients from our PFBC cohort with clinical assessment, brain imaging and genetic testing.

Results: We report two patients with a single JAM2 variant associated with brain calcifications and parkinsonism. The first patient is a 38-year-old male with a 5-year history of mild tremor and bradykinesia in the right upper limb. His family and past medical history were unremarkable. A CT scan documented extensive calcification of basal ganglia and cerebral subcortical white matter. Genetic analysis (NGS) showed a heterozygous variant (c.730G>A; p.Val244Ile) classified as VUS and predicted to be possible pathogenic by in silico prediction tools. Neuropsychological assessment showed a normal cognitive profile.
The second patient presented at 53 years with rest tremor and bradykinesia of the left arm associated with brisk tendon reflexes and Hoffmann sign. Symptoms were improved by Levodopa administration. A brain CT scan showed bilateral internal pallidal calcifications. DaTSCAN documented reduced tracer uptake in the globus pallidus bilaterally and in the right caudate nucleus. NGS analysis revealed a heterozygous variant c.872G>C (p.Trp291Ser) of JAM2, classified as a VUS but predicted in silico to be possibly pathogenic. Neuropsychological assessment was normal.
CNV analysis failed to detect a second variant in both patients.

Conclusion: Monoallelic JAM2 variants may be clinically relevant and cause mild phenotypes associated with cerebral calcifications. Unknown intronic variants may be present but not detected by NGS panels. It might be possible that other unknown variants could play a key role in the modulation of clinical spectrum.

Cattura

dat scan

To cite this abstract in AMA style:

S. Andretta, G. Bonato, M. Mainardi, L. Salviati, A. Antonini, M. Carecchio. Symptomatic brain calcifications in two patients with JAM2 monoallelic variants. [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/symptomatic-brain-calcifications-in-two-patients-with-jam2-monoallelic-variants/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/symptomatic-brain-calcifications-in-two-patients-with-jam2-monoallelic-variants/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley